Reviews Tinzaparin


No reviews yet.

Innohep Drug Description
Innohep®
(tinzaparin sodium) Injection
For Subcutaneous (SC) Use Only

WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated
with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term
or permanent paralysis. Consider these risks when scheduling patients for spinal
procedures. Factors that can increase the risk of developing epidural or spinal
hematomas in these patients include:

Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal
anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment.
If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients
anticoagulated or to be anticoagulated for thromboprophylaxis (see WARNINGS,
Hemorrhage, and PRECAUTIONS: DRUG INTERACTIONS).

DRUG DESCRIPTION



What are the possible side effects of tinzaparin (Innohep)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using tinzaparin and call your doctor at once if you have any of these serious side effects:

unusual bleeding such as nosebleeds, bleeding gums, or any bleeding that will not stop;
pale skin, weakness, easy bruising, purple or red pinpoint spots under your skin;
unexpected vaginal bleeding;
blood...
Read All Potential Side Effects for Innohep »




INNOHEP® is a sterile solution, containing tinzaparin sodium, a low molecular weight heparin. It is available in a multiple dose 2 mL vial.
Each 2 mL vial contains 20,000 anti-Factor Xa IU (anti-Xa) of tinzaparin sodium per mL, for a total of 40,000 IU, and 3.1 mg/mL sodium metabisulfite as a stabilizer. The vial contains 10 mg/mL benzyl alcohol as a preservative. Sodium hydroxide may be added to achieve a pH range of 5.0 to 7.5.
Table 1: Composition of 20,000 anti-Xa IU/mL INNOHEP®
(tinzaparin sodium injection)



Component
Quantity per mL


Tinzaparin sodium
20,000 anti-Xa IU


Benzyl alcohol, USP
10 mg


Sodium metabisulfite, USP
3.106 mg1


Sodium hydroxide, USP
as necessary


Water for Injection, USP
q.s. to 1 mL


1 Corresponding to 3.4 mg/mL sodium bisulfite



Tinzaparin sodium is the sodium salt of a low molecular weight heparin obtained
by controlled enzymatic depolymerization of heparin from porcine intestinal
mucosa using heparinase from Flavobacterium heparinum. The majority of
the components have a 2-O-sulpho-4-enepyranosuronic acid structure at the non-reducing
end and a 2-N,6-O-disulpho-D-glucosamine structure at the reducing end of the
chain.
Potency is determined by means of a biological assay and interpreted by the
first International Low Molecular Weight Heparin Standard as units of anti-factor
Xa (anti-Xa) activity per milligram. The mean tinzaparin sodium anti-factor
Xa activity is approximately 100 IU per milligram. The average molecular weight
ranges between 5,500 and 7,500 daltons. The molecular weight distribution is:
<2,000             Daltons
      <10%
2,000 to 8,000 Daltons       60% to 72%
>8,000             Daltons
      22% to 36%
Structural Formula:







Last reviewed on RxList: 1/7/2010




Innohep Drug Description
Innohep®
(tinzaparin sodium) Injection
For Subcutaneous (SC) Use Only

WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated
with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term
or permanent paralysis. Consider these risks when scheduling patients for spinal
procedures. Factors that can increase the risk of developing epidural or spinal
hematomas in these patients include:

Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal
anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment.
If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients
anticoagulated or to be anticoagulated for thromboprophylaxis (see WARNINGS,
Hemorrhage, and PRECAUTIONS: DRUG INTERACTIONS).

DRUG DESCRIPTION



What are the possible side effects of tinzaparin (Innohep)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using tinzaparin and call your doctor at once if you have any of these serious side effects:

unusual bleeding such as nosebleeds, bleeding gums, or any bleeding that will not stop;
pale skin, weakness, easy bruising, purple or red pinpoint spots under your skin;
unexpected vaginal bleeding;
blood...
Read All Potential Side Effects for Innohep »




INNOHEP® is a sterile solution, containing tinzaparin sodium, a low molecular weight heparin. It is available in a multiple dose 2 mL vial.
Each 2 mL vial contains 20,000 anti-Factor Xa IU (anti-Xa) of tinzaparin sodium per mL, for a total of 40,000 IU, and 3.1 mg/mL sodium metabisulfite as a stabilizer. The vial contains 10 mg/mL benzyl alcohol as a preservative. Sodium hydroxide may be added to achieve a pH range of 5.0 to 7.5.
Table 1: Composition of 20,000 anti-Xa IU/mL INNOHEP®
(tinzaparin sodium injection)



Component
Quantity per mL


Tinzaparin sodium
20,000 anti-Xa IU


Benzyl alcohol, USP
10 mg


Sodium metabisulfite, USP
3.106 mg1


Sodium hydroxide, USP
as necessary


Water for Injection, USP
q.s. to 1 mL


1 Corresponding to 3.4 mg/mL sodium bisulfite



Tinzaparin sodium is the sodium salt of a low molecular weight heparin obtained
by controlled enzymatic depolymerization of heparin from porcine intestinal
mucosa using heparinase from Flavobacterium heparinum. The majority of
the components have a 2-O-sulpho-4-enepyranosuronic acid structure at the non-reducing
end and a 2-N,6-O-disulpho-D-glucosamine structure at the reducing end of the
chain.
Potency is determined by means of a biological assay and interpreted by the
first International Low Molecular Weight Heparin Standard as units of anti-factor
Xa (anti-Xa) activity per milligram. The mean tinzaparin sodium anti-factor
Xa activity is approximately 100 IU per milligram. The average molecular weight
ranges between 5,500 and 7,500 daltons. The molecular weight distribution is:
<2,000             Daltons
      <10%
2,000 to 8,000 Daltons       60% to 72%
>8,000             Daltons
      22% to 36%
Structural Formula:







Last reviewed on RxList: 1/7/2010




Innohep Drug Description
Innohep®
(tinzaparin sodium) Injection
For Subcutaneous (SC) Use Only

WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated
with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term
or permanent paralysis. Consider these risks when scheduling patients for spinal
procedures. Factors that can increase the risk of developing epidural or spinal
hematomas in these patients include:

Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal
anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment.
If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients
anticoagulated or to be anticoagulated for thromboprophylaxis (see WARNINGS,
Hemorrhage, and PRECAUTIONS: DRUG INTERACTIONS).

DRUG DESCRIPTION



What are the possible side effects of tinzaparin (Innohep)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using tinzaparin and call your doctor at once if you have any of these serious side effects:

unusual bleeding such as nosebleeds, bleeding gums, or any bleeding that will not stop;
pale skin, weakness, easy bruising, purple or red pinpoint spots under your skin;
unexpected vaginal bleeding;
blood...
Read All Potential Side Effects for Innohep »




INNOHEP® is a sterile solution, containing tinzaparin sodium, a low molecular weight heparin. It is available in a multiple dose 2 mL vial.
Each 2 mL vial contains 20,000 anti-Factor Xa IU (anti-Xa) of tinzaparin sodium per mL, for a total of 40,000 IU, and 3.1 mg/mL sodium metabisulfite as a stabilizer. The vial contains 10 mg/mL benzyl alcohol as a preservative. Sodium hydroxide may be added to achieve a pH range of 5.0 to 7.5.
Table 1: Composition of 20,000 anti-Xa IU/mL INNOHEP®
(tinzaparin sodium injection)



Component
Quantity per mL


Tinzaparin sodium
20,000 anti-Xa IU


Benzyl alcohol, USP
10 mg


Sodium metabisulfite, USP
3.106 mg1


Sodium hydroxide, USP
as necessary


Water for Injection, USP
q.s. to 1 mL


1 Corresponding to 3.4 mg/mL sodium bisulfite



Tinzaparin sodium is the sodium salt of a low molecular weight heparin obtained
by controlled enzymatic depolymerization of heparin from porcine intestinal
mucosa using heparinase from Flavobacterium heparinum. The majority of
the components have a 2-O-sulpho-4-enepyranosuronic acid structure at the non-reducing
end and a 2-N,6-O-disulpho-D-glucosamine structure at the reducing end of the
chain.
Potency is determined by means of a biological assay and interpreted by the
first International Low Molecular Weight Heparin Standard as units of anti-factor
Xa (anti-Xa) activity per milligram. The mean tinzaparin sodium anti-factor
Xa activity is approximately 100 IU per milligram. The average molecular weight
ranges between 5,500 and 7,500 daltons. The molecular weight distribution is:
<2,000             Daltons
      <10%
2,000 to 8,000 Daltons       60% to 72%
>8,000             Daltons
      22% to 36%
Structural Formula:







Last reviewed on RxList: 1/7/2010




Innohep Drug Description
Innohep®
(tinzaparin sodium) Injection
For Subcutaneous (SC) Use Only

WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated
with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term
or permanent paralysis. Consider these risks when scheduling patients for spinal
procedures. Factors that can increase the risk of developing epidural or spinal
hematomas in these patients include:

Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal
anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment.
If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients
anticoagulated or to be anticoagulated for thromboprophylaxis (see WARNINGS,
Hemorrhage, and PRECAUTIONS: DRUG INTERACTIONS).

DRUG DESCRIPTION



What are the possible side effects of tinzaparin (Innohep)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using tinzaparin and call your doctor at once if you have any of these serious side effects:

unusual bleeding such as nosebleeds, bleeding gums, or any bleeding that will not stop;
pale skin, weakness, easy bruising, purple or red pinpoint spots under your skin;
unexpected vaginal bleeding;
blood...
Read All Potential Side Effects for Innohep »




INNOHEP® is a sterile solution, containing tinzaparin sodium, a low molecular weight heparin. It is available in a multiple dose 2 mL vial.
Each 2 mL vial contains 20,000 anti-Factor Xa IU (anti-Xa) of tinzaparin sodium per mL, for a total of 40,000 IU, and 3.1 mg/mL sodium metabisulfite as a stabilizer. The vial contains 10 mg/mL benzyl alcohol as a preservative. Sodium hydroxide may be added to achieve a pH range of 5.0 to 7.5.
Table 1: Composition of 20,000 anti-Xa IU/mL INNOHEP®
(tinzaparin sodium injection)



Component
Quantity per mL


Tinzaparin sodium
20,000 anti-Xa IU


Benzyl alcohol, USP
10 mg


Sodium metabisulfite, USP
3.106 mg1


Sodium hydroxide, USP
as necessary


Water for Injection, USP
q.s. to 1 mL


1 Corresponding to 3.4 mg/mL sodium bisulfite



Tinzaparin sodium is the sodium salt of a low molecular weight heparin obtained
by controlled enzymatic depolymerization of heparin from porcine intestinal
mucosa using heparinase from Flavobacterium heparinum. The majority of
the components have a 2-O-sulpho-4-enepyranosuronic acid structure at the non-reducing
end and a 2-N,6-O-disulpho-D-glucosamine structure at the reducing end of the
chain.
Potency is determined by means of a biological assay and interpreted by the
first International Low Molecular Weight Heparin Standard as units of anti-factor
Xa (anti-Xa) activity per milligram. The mean tinzaparin sodium anti-factor
Xa activity is approximately 100 IU per milligram. The average molecular weight
ranges between 5,500 and 7,500 daltons. The molecular weight distribution is:
<2,000             Daltons
      <10%
2,000 to 8,000 Daltons       60% to 72%
>8,000             Daltons
      22% to 36%
Structural Formula:







Last reviewed on RxList: 1/7/2010




Innohep Drug Description
Innohep®
(tinzaparin sodium) Injection
For Subcutaneous (SC) Use Only

WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated
with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term
or permanent paralysis. Consider these risks when scheduling patients for spinal
procedures. Factors that can increase the risk of developing epidural or spinal
hematomas in these patients include:

Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal
anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment.
If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients
anticoagulated or to be anticoagulated for thromboprophylaxis (see WARNINGS,
Hemorrhage, and PRECAUTIONS: DRUG INTERACTIONS).

DRUG DESCRIPTION



What are the possible side effects of tinzaparin (Innohep)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using tinzaparin and call your doctor at once if you have any of these serious side effects:

unusual bleeding such as nosebleeds, bleeding gums, or any bleeding that will not stop;
pale skin, weakness, easy bruising, purple or red pinpoint spots under your skin;
unexpected vaginal bleeding;
blood...
Read All Potential Side Effects for Innohep »




INNOHEP® is a sterile solution, containing tinzaparin sodium, a low molecular weight heparin. It is available in a multiple dose 2 mL vial.
Each 2 mL vial contains 20,000 anti-Factor Xa IU (anti-Xa) of tinzaparin sodium per mL, for a total of 40,000 IU, and 3.1 mg/mL sodium metabisulfite as a stabilizer. The vial contains 10 mg/mL benzyl alcohol as a preservative. Sodium hydroxide may be added to achieve a pH range of 5.0 to 7.5.
Table 1: Composition of 20,000 anti-Xa IU/mL INNOHEP®
(tinzaparin sodium injection)



Component
Quantity per mL


Tinzaparin sodium
20,000 anti-Xa IU


Benzyl alcohol, USP
10 mg


Sodium metabisulfite, USP
3.106 mg1


Sodium hydroxide, USP
as necessary


Water for Injection, USP
q.s. to 1 mL


1 Corresponding to 3.4 mg/mL sodium bisulfite



Tinzaparin sodium is the sodium salt of a low molecular weight heparin obtained
by controlled enzymatic depolymerization of heparin from porcine intestinal
mucosa using heparinase from Flavobacterium heparinum. The majority of
the components have a 2-O-sulpho-4-enepyranosuronic acid structure at the non-reducing
end and a 2-N,6-O-disulpho-D-glucosamine structure at the reducing end of the
chain.
Potency is determined by means of a biological assay and interpreted by the
first International Low Molecular Weight Heparin Standard as units of anti-factor
Xa (anti-Xa) activity per milligram. The mean tinzaparin sodium anti-factor
Xa activity is approximately 100 IU per milligram. The average molecular weight
ranges between 5,500 and 7,500 daltons. The molecular weight distribution is:
<2,000             Daltons
      <10%
2,000 to 8,000 Daltons       60% to 72%
>8,000             Daltons
      22% to 36%
Structural Formula:







Last reviewed on RxList: 1/7/2010





Other reviews about Tinzaparin on wordpress

Day 167 - Wednesday 12th October
  by karensstory
After yesterday, I was knackered, and kp kept asking me if anything was wrong today. I just kept reassuring her I was just tired. I didn't arrive until […]


Joint Commission Speaks to Anticoagulant Error Prevention
  by Christopher Little
Anyone interested in patient safety when it comes to proper dosing should read this report from Issue 41 of JCAHO (the Joint Commission on the Accreditation of Hospitals). […]


Medication Use Management
  by heatherchui
Objectives/Activities 1. The resident will become familiar with various facets of Medication Use Management by completing the following activities: a. Complete assigned didactic pre‐readings and be prepared […]


Medication Use Management Wrap Up
  by heatherchui
Today, I attended didactic sessions as the final requirement for the Medication Use Management rotation. Although the material could have been really "dry", Richard and Lara managed to […]


Medicine- Day 11
  by leungsy
Today, I lead a journal club discussion on the use of dabigatran vs warfarin in afib patients at risk of experiencing a stroke. My journal CONSORT assessment is […]


FDA MedWatch - December 2009 Drug Safety Labeling Changes
  by irbtipoftheweek
The MedWatch December 2009 Drug Safety Labeling Changes posting includes 28 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, […]


Emerg- Day 3
  by leungsy
Heparin in Renal Failure unfractionated heparin is ok poor creatinine clearance ( less than 30 ml/min) is an independent risk factor for bleed Prophylaxis: LMWH should be ok Treatment: not all LMWH […]


PolyMedic, Inc. (OTCBB: PYMX) $85M (MarketCap)
  by World Market Media
PolyMedix, Inc. (OTCBB: PYMX) is an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases. Today, it announced its successful […]


PolyMedic, Inc. (OTCBB: PYMX) $85M (MarketCap) Successfully Completes Phase 1B Clinical Study
  by 1castex
Herapin is an iv anticoagulant used to prevent clots from forming during certain cardiothoracic and orthopedic surgical procedures After these procedures the anticoagulant activity of heparin must be […]


Nephrology - week 3 & 4
  by haleygill
I've been pretty independent on my last few weeks of nephrology. I have been working on the inpatient nephrology ward and rounding with the team on my own. […]



Other reviews about Tinzaparin on web:

Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep or innohep world wide. It has been approved by the U.S. Food ... Tinzaparin sodium - Wikipedia, the free encyclopedia


Consumer information about the medication TINZAPARIN - INJECTION (Innohep), includes side effects, drug interactions, recommended dosages, and storage information. Read more ... TINZAPARIN - INJECTION (Innohep) side effects, medical uses, and ...


Learn about the prescription medication Innohep (Tinzaparin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Innohep (Tinzaparin) Drug Information: Uses, Side Effects, Drug ...


Physician reviewed tinzaparin patient information - includes tinzaparin description, dosage and directions. tinzaparin medical facts from Drugs.com


All about Tinzaparin. View complete and up to date Tinzaparin information - part of the Drugs.com trusted medication database. Tinzaparin Facts and Comparisons at Drugs.com


Tinzaparin Brand names: Innohep® Drug Forms: Tinzaparin injection (below) Tinzaparin Sodium Solution for injection Español: Inyección de Tinzaparin sodium: Information from Answers.com


Pronunciation: tin ZA pa rin Brand: Innohep What is the most important information I should know about tinzaparin? /EF/1813AC397E8E4DE9587B4FC913760.g tinzaparin - MSN Health & Fitness - Medications


Mayo Clinic offers award-winning medical and health information and tools for healthy living. Tinzaparin (Subcutaneous Route) - MayoClinic.com


Tinzaparin is a blood thinner (anticoagulant) that prevents blood clots from forming in the body. tinzaparin Information - Drugs and Treatments - MedHelp


Tinzaparin is a type of anticoagulant used to treat blood clots. This part of the eMedTV Web site takes an in-depth look at this prescription drug, with information on dosing ... Tinzaparin





Featured Reviews

Reviews Nystatin Oral Suspension

Nystatin Oral Suspension Drug Description Nystatin Oral Suspension, USP DRUG DESCRIPTION What are the possible side effects of nystatin (Bio-Statin, Mycostatin, Mycostatin Pastilles, Nilstat)? Stop taking nystatin and seek emergency...
Read More  |  Review This
Reviews Pentoxifylline

Trental Drug Description TRENTAL® (pentoxifylline) Tablets, 400 mg DRUG DESCRIPTION What are the possible side effects of pentoxifylline (Pentoxil, Trental)? If you experience any of the following serious side effects, stop...
Read More  |  Review This
Reviews Eloxatin

Eloxatin Drug Description ELOXATIN (oxaliplatin) Powder, for Solution for Intravenous use ELOXATIN (oxaliplatin) Concentrate, for Solution for Intravenous use WARNING ANAPHYLACTIC REACTIONS Anaphylactic reactions to ELOXATIN have been...
Read More  |  Review This
Reviews Phosphocol

Phosphocol Drug Description Phosphocol® P 32 (chromic phosphate P 32) Suspension Therapeutic intraperitoneal or intracavitary injection only for treatment of peritoneal or pleural effusions caused by metastatic disease. DRUG...
Read More  |  Review This
Reviews Milnacipran HCl Tablets

Savella Drug Description Savella® (milnacipran HCl) Tablets WARNING SUICIDALITY AND ANTIDEPRESSANT DRUGS Savella is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....